Decreased Expression of Bone Morphogenetic Protein (BMP) Receptor Type II Correlates with Insensitivity to BMP-6 in Human Renal Cell Carcinoma Cells

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 6046-6051

  Kim, Isaac Yi ^a,b   Lee, Dong Hyeon ^c   Lee, Dug Keun ^b   Kim, Byung Chul ^b   Kim, Heung Tae ^b   Leach, Fredrick S ^b   Linehan, W Marston ^c   Morton, Ronald A ^a   Kim, Seong Jin ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BONE MORPHOGENETIC PROTEIN RECEPTOR IA; BONE MORPHOGENETIC PROTEIN RECEPTOR IB; GROWTH FACTOR; LIPOFECTAMINE; LUCIFERASE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE CONSTRUCT; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; NORTHERN BLOTTING; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

BLOTTING, NORTHERN; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CARCINOMA, RENAL CELL; DOWN-REGULATION; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0346734279     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
2. Katz, D. L., Zheng, T., Holford, T. R., and Flannery, J. Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989. Int. J. Cancer, 58: 57-63, 1994,
3. Waters, W. B., and Richie, J. P. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J. Urol., 122: 306-309, 1979.
4. Ljungberg, B., Alamdari, F. I., Rasmuson, T., and Roos, G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int., 84: 405-411, 1999.
5. American Cancer Society. Results in treating cancer. Report no. 12. Kidney cancer. Chicago: American Cancer Society, 1989.
6. Motzer, R. J., Mazumdar, M., Bacik, J., Russo, P., Berg, W. J., and Metz, E. M. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol., 18: 1928-1935, 2000.
7. Motzer, R. J., and Russo, P. Systemic therapy for renal cell carcinoma. J. Urol., 163: 408-417, 2000.
8. Woznëy, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M., and Wang, E. A. Novel regulators of bone formation: molecular clones and activities. Science (Wash. DC), 242: 1528-1534, 1988.
9. Sampath, T. K., Maliakal, J. C., Hauschka, P. V., Jones, W. K., Sasak, H., Tucker, R. F., White, K. H., Coughlin, J. E., Tucker, M. M., and Pang, R. H. L. Recombinant human osteogenic protein-1 (OP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J. Biol. Chem., 267: 20352-20362, 1992.
10. Hogan, B. L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev., 10: 1580-1594, 1996.
11. Liu, F., Ventura, F., Doody, J., and Massague, J. Human type II receptor for bone morphogenetic proteins (BMPs): extension of the two-kinase receptor model to BMPs. Mol. Cell. Biol., 15: 3479-3486, 1995.
12. Yamashita, H., ten Dijke, P., Heldin, C. H., and Miyazono, K. Bone morphogenetic protein receptors. Bone, 19: 569-574, 1996.
13. ten Dijke, P., Yamashita, H., Sampath, T. K., Reddi, A. H., Esterez, M., Riddle, D. L., Ichijo, H., Heldin, C. H., and Miyazono, K. Introduction of type I receptors for osteogenic protein-I and bone morphogenetic protein-4. J. Biol. Chem., 269: 16985-16988, 1994.
14. Dudley, A. T., Lyons, K. M., and Robertson, E. J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev., 9: 2795-2807, 1995.
15. Miyazaki, Y., Oshima, K., Fogo, A., Hogan, B. L. M., and Ichikawa, I. Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter. J. Clin. Investig., 7: 863-873, 2000.
16. Gupta, I. R., Macias-Silva, M., Kim, S., Zhou, X., Piscione, T. D., Whiteside, C., Wrana, J. L., and Rosenblum, N. D. BMP-2/ALK3 and HGF signal in parallel to regulate renal collecting duct morphogenesis. J. Cell Science, 113: 269-278, 2000.
17. Dewulf, N., Verschueren, K., Lonnoy, O., Moren, A., Grimsby, S., Vande Spiegel, K., Miyazono, K., Huylebroeck, D., and ten Dijke, P. Distinct spatial and temporal expression pattern of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology, 136: 2652-2663, 1995.
18. Bosukonda, D., Shih M-S, Sampath, T. K. and Vukicevic, S. Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys. Kidney Int., 58: 1902-1911, 2000.
19. Anglard, P., Trahan, E., Liu, S., Latif, F., Merino, M. J., Lerman, M. I., Zbar, B., and Linehan, W. M. Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res., 52: 348-356, 1992.
20. Jonk, L. J., Itoh, S., Heldin, C-H., ten Dijke, P., and Kruijer, W. Identification and functional characterization of a smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem., 273: 21145-21152, 1998.